Latham & Watkins Advises IRRAS on Sale to ClearPoint Neuro

Latham & Watkins advised IRRAS Holdings Inc. in connection with the sale of the company to ClearPoint Neuro, Inc. IRRAS Holdings Inc., a medical device company specializing in neurocritical care, has completed the sale of 100% of its shares to ClearPoint Neuro, Inc. (NASDAQ: CLPT). The consideration consists of a mix of cash and shares of ClearPoint common stock, together with additional earnout payments based on net sales after closing. The ClearPoint shares delivered to IRRAS stockholders may be sold pursuant to a registration statement that ClearPoint will file with the U.S. Securities and Exchange Commission after closing. The strategic transaction is expected to enable IRRAS to expand its market presence and enhance its commercial capabilities as part of the ClearPoint portfolio. Latham & Watkins represented IRRAS Holdings Inc. with a team composed by: New York partner Eli Curi (corporate), Los Angeles partner Brian Duff (corporate), associate Drew O’Sullivan (corporate) and with assistance from Donara Aghajani. Advice on tax matters was provided by Washington, D.C. partner Andrea Ramezan-Jackson (tax). Advice on benefits matters was provided by Silicon Valley partner James Robinson (benefits).

Latham & Watkins Advises IRRAS on Sale to ClearPoint Neuro

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads